Alberto Lleó

Dr. Alberto Lleó is the director of the Memory Unit of the Neurology Department at Hospital de la Santa Creu i Sant Pau.

After obtaining his Medical degree from the University of Barcelona, he completed his specialization in Neurology at Hospital de la Santa Creu i Sant Pau in 2000. Two years later, he obtained his PhD in Medicine at the University of Barcelona and continued his education with a clinical and basic research fellowship on memory and movement disorders at the Massachusetts General Hospital, Boston (2002-2004) where he combined clinical and research tasks.

In his professional career, Dr. Alberto Lleó has combined his clinical activity with translational research projects in the field of dementias with a specific focus on the molecular bases of the disease and biomarker development. Some of his main contributions are the discovery of new genetic alterations in Alzheimer’s disease, the study of the gamma-secretase complex, and the assessment of new chemical biomarkers for Alzheimer’s disease and frontotemporal dementia.

Today, Dr. Alberto Lleó runs a translational group, leads many projects funded by public and private agencies, and collaborates regularly with numerous national and international research groups. He also coordinates the Alzheimer program of CIBERNED (Center for Networked Biomedical Research in Neurodegenerative Diseases). To date, he has authored more than 20 book chapters and over 150 publications in international journals, and his contributions have been awarded by the Spanish Society of Neurology.

Recent Publications

  1. Quality of Life and the Experience of Living with Early-Stage Alzheimer's Disease. Villarejo-Galende, A, García-Arcelay, E, Piñol-Ripoll, G et al. J Alzheimers Dis 2022
    PMID:36155523

  2. Genome-wide meta-analysis for Alzheimer's disease cerebrospinal fluid biomarkers. Jansen, IE, van der Lee, SJ, Gomez-Fonseca, D et al. Acta Neuropathol 2022
    PMID:36066633

  3. Neural correlates of episodic memory in adults with Down syndrome and Alzheimer's disease. Benejam, B, Aranha, MR, Videla, L et al. Alzheimers Res Ther 2022
    PMID:36057615

  4. Enrichment of Astrocyte-Derived Extracellular Vesicles from Human Plasma. Valle-Tamayo, N, Pérez-González, R, Chiva-Blanch, G et al. J Vis Exp 2022
    PMID:35993755

  5. Longitudinal Clinical and Cognitive Changes Along the Alzheimer Disease Continuum in Down Syndrome. Videla, L, Benejam, B, Pegueroles, J et al. JAMA Netw Open 2022
    PMID:35930282

  6. The use of lumbar puncture and safety recommendations in Alzheimer's disease: a plain language summary. Hampel, H, Elhage, A, Shaw, LM et al. Neurodegener Dis Manag 2022
    PMID:35866715

  7. Intermediate and Expanded HTT Alleles and the Risk for α-Synucleinopathies. Pérez-Oliveira, S, Álvarez, I, Rosas, I et al. Mov Disord 2022
    PMID:35852957

  8. Establishing In-House Cutoffs of CSF Alzheimer's Disease Biomarkers for the AT(N) Stratification of the Alzheimer Center Barcelona Cohort. Orellana, A, García-González, P, Valero, S et al. Int J Mol Sci 2022
    PMID:35805894

  9. Myelin loss in C9orf72 hexanucleotide expansion carriers. Sirisi, S, Querol-Vilaseca, M, Dols-Icardo, O et al. J Neurosci Res 2022
    PMID:35766328

  10. Leveraging large multi-center cohorts of Alzheimer disease endophenotypes to understand the role of Klotho heterozygosity on disease risk. Ali, M, Sung, YJ, Wang, F et al. PLoS One 2022
    PMID:35617280

  11. Association of Alzheimer Disease With Life Expectancy in People With Down Syndrome. Iulita, MF, Garzón Chavez, D, Klitgaard Christensen, M et al. JAMA Netw Open 2022
    PMID:35604690

  12. Correction: Cerebrospinal fluid tau levels are associated with abnormal neuronal plasticity markers in Alzheimer's disease. Visser, PJ, Reus, LM, Gobom, J et al. Mol Neurodegener 2022
    PMID:35550177

  13. Diagnostic Accuracy of Magnetic Resonance Imaging Measures of Brain Atrophy Across the Spectrum of Progressive Supranuclear Palsy and Corticobasal Degeneration. Illán-Gala, I, Nigro, S, VandeVrede, L et al. JAMA Netw Open 2022
    PMID:35486397

  14. Importance of cerebrospinal fluid storage conditions for the Alzheimer's disease diagnostics on an automated platform. Ferrer, R, Zhu, N, Arranz, J et al. Clin Chem Lab Med 2022
    PMID:35405043

  15. Multimarker synaptic protein cerebrospinal fluid panels reflect TDP-43 pathology and cognitive performance in a pathological cohort of frontotemporal lobar degeneration. Cervantes González, A, Irwin, DJ, Alcolea, D et al. Mol Neurodegener 2022
    PMID:35395770

Search PubMed